



4
Kee
(2)
H
33

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1275A)

In re Application of:)	
)	
Lawton et al.)	
)	
Serial No.: 09/281,760)	Examiner: Jamroz, M.
)	
Filed: March 30, 1999)	Art Unit: 1644
)	

For: **SPECIFIC BINDING PROTEINS FOR TREATING CANINE ALLERGY**

DECLARATION

Commissioner for Patents
Washington, D.C. 20231

Sir:

1. I, Regis Krah, a Research Scientist employed at IDEXX Laboratories, Inc., declare:
2. A hybridoma that produces a monoclonal antibody described as "8H.8" in U.S. Patent Application Ser. No. 09/281,760 has been deposited with the American Type Culture Collection (ATCC) 10801 University Blvd., Manassas, Virginia 20110, USA, under the terms of the Budapest Treaty on August 13, 2002.
3. The hybridoma has been received by the ATCC and reference number PTA-4597 has been assigned to the hybridoma.

4. The hybridoma deposited with the ATCC on August 13, 2002 has been in the custody and control of IDEXX Laboratories since at least April 9, 1998 and that the hybridoma deposited with the ATCC on August 13, 2002 is the same material that was in the possession of IDEXX Laboratories since at least April 9, 1998. This 8H.8 producing hybridoma is the same as that described in U.S. Patent Application Ser. No. 09/281,760.
5. The hybridoma that produces 8H.8 monoclonal antibody will be irrevocably and without restriction or condition released to the public upon issuance of a patent. The deposit will be maintained by the ATCC for a period of 30 years after the date of the deposit, 5 years after the last request for a sample, or for the enforceable life of the patent, whichever is longer.
6. I hereby certify that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Date: Oct 1, 2002


Regis Krah



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1275A)

In re Application of:)	
)	
Lawton et al.)	
)	
Serial No.: 09/281,760)	Examiner: Jamroz, M.
)	
Filed: March 30, 1999)	Art Unit: 1644
)	

For: **SPECIFIC BINDING PROTEINS FOR TREATING CANINE ALLERGY**

DECLARATION

Commissioner for Patents
Washington, D.C. 20231


Sir:

1. I, Lisa M.W. Hillman, have been appointed by the Applicants of the above-referenced application to prosecute the application before the United States Patent and Trademark Office.
2. The C-terminal 71 amino acids of exon 3 of canine IgE has been incorporated into the above-mentioned application by reference to, *inter alia*, U.S. Patent Application 09/146,400 filed 9/3/1998. SEQ ID NO:4 of U.S. Patent Application 09/146,400, which comprises exon 3 of canine IgE has been added into the text of the present application as SEQ ID NOs:33-39. Reference to newly added SEQ ID NOs:33-39 has been added to page 24 of

the specification and the sequence listing has been updated to include SEQ ID NOs:33-39.

3. The amendatory material that has been incorporated by reference consists of the same material incorporated by reference in the referencing application.
4. I hereby certify that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Date: Oct 7, 2002



Lisa M.W. Hillman
Reg. No. 43,673